Assessing fidelity of treatment delivery in group and individual 12-step facilitation

• DOI: 10.1016/j.jsat.2012.07.003
• Publication Date: 2012-09-01T05:50:31Z
• Authors: Barbara K. Campbell; Jennifer K. Manuel; Sarah Turcotte Ma...; K. Michelle Peavy; Julija Stelmokas; Dennis McCarty; Joseph R. Guydish
• Keywords: Adult; Male; Substance-Related Disorders; 610; 12-Step facilitation; Clinical Research; Behavioral and Social Science; Psychology; Humans; 0501 psychology and cognitive sciences; Treatment fidelity; Clinical and Health Psychology; 05 social sciences; Reproducibility of Results; Middle Aged; 3. Good health; Psychotherapy; Self-Help Groups; Coding system; Psychotherapy, Group; Patient Compliance; Female; Group; Clinical Competence; Guideline Adherence; Substance Abuse Treatment Centers; Empathy; Delivery of Health Care

Twelve step facilitation (TSF) is an emerging, empirically supported treatment, the study of which will be strengthened by rigorous fidelity assessment. This report describes the development, reliability and concurrent validity of the Twelve Step Facilitation Adherence Competence Empathy Scale (TSF ACES), a comprehensive fidelity rating scale for group and individual TSF treatment developed for the National Drug Abuse Treatment Clinical Trials Network study, Stimulant Abuser Groups to Engage in 12-Step. Independent raters used TSF ACES to rate treatment delivery fidelity of 966 (97% of total) TSF group and individual sessions. TSF ACES summary measures assessed therapist treatment adherence, competence, proscribed behaviors, empathy and overall session performance. TSF ACES showed fair to good overall reliability; weighted kappa coefficients for 59 co-rated sessions ranged from .31 to 1.00, with a mean of .69. Reliability ratings for session summary measures were good to excellent (.69-.91). Internal consistency for the instrument was variable (.47-.71). Relationships of the TSF ACES summary measures with each other, as well as relationships of the summary measures with a measure of therapeutic alliance provided support for concurrent and convergent validity. Implications and future directions for the use of TSF ACES in clinical trials and community treatment implementation are discussed.